Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other research analysts have also issued reports on KROS. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. TD Cowen raised Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Oppenheimer reiterated an “outperform” rating and issued a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday. Finally, Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $21.86.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $11.30 on Friday. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $22.55. The stock has a market capitalization of $344.31 million, a P/E ratio of 6.21 and a beta of 0.87. The company’s 50-day moving average is $17.41 and its 200 day moving average is $17.04.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The company had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $3.66 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The business’s quarterly revenue was down 87.2% on a year-over-year basis. During the same quarter last year, the business earned ($1.14) earnings per share. Research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. The Manufacturers Life Insurance Company increased its holdings in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares in the last quarter. UBS Group AG raised its stake in shares of Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after purchasing an additional 1,091 shares during the last quarter. Strs Ohio lifted its holdings in shares of Keros Therapeutics by 3.9% during the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. purchased a new stake in shares of Keros Therapeutics during the fourth quarter valued at $29,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.